Amyloidosis-recent developments

Seminars in Arthritis and Rheumatism

Volumn 39, Issue 5, 2010, Pages 356-368

  Pettersson, Tom ^a   Konttinen, Yrjö T ^a,b,c  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b ORTON Invalid Foundation   (Finland)

^c COXA Hospital for Joint Replacement ^*  (Finland)

Author keywords

Amyloidosis; Disease severity score; Inflammation; Pathogenesis; Plasma cell dyscrasias

Indexed keywords

AMYLOID PRECURSOR PROTEIN; AMYLOID PROTEIN; ANTIRHEUMATIC AGENT; BLOOD CLOTTING FACTOR; CIPROFLOXACIN; COLCHICINE; CONGO RED; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; ERYTHROMYCIN; ETANERCEPT; FIBRINOGEN; FLUDROCORTISONE; FRESH FROZEN PLASMA; HYPERTENSIVE FACTOR; LOOP DIURETIC AGENT; MELPHALAN; METOCLOPRAMIDE; METRONIDAZOLE; OCTREOTIDE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SPIRONOLACTONE; THALIDOMIDE; TUMOR NECROSIS FACTOR INHIBITOR; UNINDEXED DRUG; VINCRISTINE;

AMINO ACID SEQUENCE; AMYLOIDOSIS; ARTIFICIAL HEART PACEMAKER; BIOCHEMISTRY; BIREFRINGENCE; BLOOD CLOTTING FACTOR DEFICIENCY; BONE MARROW BIOPSY; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DEHYDRATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIET SUPPLEMENTATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; FAMILIAL MEDITERRANEAN FEVER; FAMILY HISTORY; GASTROINTESTINAL MOTILITY DISORDER; GENETIC ANALYSIS; HEART FAILURE; HEMODIALYSIS; HEREDITARY PERIODIC FEVER; HISTOCHEMISTRY; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LABORATORY TEST; MALNUTRITION; MICROSCOPY; NEPHROTIC SYNDROME; NUTRITIONAL DEFICIENCY; ORTHOSTATIC HYPOTENSION; PATHOGENESIS; PATHOPHYSIOLOGY; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEOMICS; PSEUDOOBSTRUCTION; REVIEW; STEM CELL TRANSPLANTATION; STRUCTURE ACTIVITY RELATION; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME;

AMYLOID; AMYLOIDOSIS; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 77949571372     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2008.09.001     Document Type: Review

References (67)

1. Merlini G., Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003, 349:583-586.
2. Buxbaum J.N. The systemic amyloidoses. Curr Opin Rheumatol 2003, 16:67-75.
3. Hirschfield G.M. Amyloidosis: a clinico-pathophysiological synopsis. Semin Cell Develop Biol 2004, 15:39-44.
4. Pepys M.B. Amyloidosis. Annu Rev Med 2006, 57:223-241.
5. Westermark P., Benson M.D., Buxbaum J.N., Cohen A.S., Frangione B., Ikeda S., et al. A primer of amyloid nomenclature. Amyloid 2007, 14:179-183.
6. Picken M.M., Hazenberg B.P.C., Obici L. Report from the diagnostic interactive session. Proceedings of the XIth International Symposium on Amyloid and Amyloidosis. Skinner M, Berk JL, Connors LH, and Seldin DC, editors 2008, 377-382. CRC Press, Boca Raton (FL). M. Skinner, J.L. Berk, L.H. Conors, D.C. Seldin (Eds.).
7. Murphy C.L., Wang S., Williams T., Weiss D.T., Solomon A. Characterization of systemic amyloid deposits by mass spectrometry. Methods Enzymol 2006, 412:48-62.
8. Pettersson T., Anttila P., Törnroth T. Renal glomerular AL and vascular AA amyloidosis in a patient with ankylosing spondylitis. Amyloid and Amyloidosis. Grateau G, Kyle RA, Skinner M, editors 2005, 284-286. CRC Press, Boca Raton (FL). G. Grateau, R.A. Kyle, M. Skinner (Eds.).
9. Landau H.J., Comenzo R.L., Zhou P., Clard B., Teruya-Feldstein J., Wang S., et al. AL amyloidosis in a patient with a T60A TTR mutation. Proceedings of the XIth International Symposium on Amyloid and Amyloidosis. Skinner M, Berk JL, Connors LH, and Seldin DC, editors 2008, 160-162. CRC Press, Boca Raton (FL). M. Skinner, J.L. Berk, L.H. Conors, D.C. Seldin (Eds.).
10. Kracker D., Litbarg N.O., Picken M.M. Amyloidosis in ankylosing spondylitis-unexpected findings underscoring the importance of typing of amyloid deposits. Proceedings of the XIth International Symposium on Amyloid and Amyloidosis. Skinner M, Berk JL, Connors LH, and Seldin DC, editors 2008, 73-74. CRC Press, Boca Raton (FL). M. Skinner, J.L. Berk, L.H. Conors, D.C. Seldin (Eds.).
11. Lachmann H.J., Booth D.R., Booth S.E., Bybee A., Gilbertson J.A., Gillmore J.D., et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002, 346:786-791.
12. Comenzo R.L., Zhou P., Fleisher M., Clark B., Teruya-Feldstein J. Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood 2006, 107:3489-3491.
13. Bellotti V., Nuvolone M., Giorgetti S., Obici L., Palladini G., Russo P., et al. The workings of the amyloid diseases. Ann Med 2007, 39:200-207.
14. Pepys M.B., Herbert J., Hutchinson W.L., Tennent G.A., Lachmann H.J., Gallimore J.L., et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002, 417:254-259.
15. Dember L.M., Hawkins P.N., Hazenberg B.P.C., Gorevic P.D., Merlini G., Butrimiene I., et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 2007, 356:2349-2360.
16. Sousa M.M., Cardoso I., Fernandes R., Guimarães A., Saraiva M.J. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol 2001, 159:1993-2000.
17. Andersson K., Olofsson A., Nielsen E.H., Svehag S.E., Lundgren E. Only amyloidogenetic intermediates of transthyretin induce apoptosis. Biochem Biophys Res Commun 2002, 294:309-314.
18. Westermark P., Benson M.D., Buxbaum J.N., Cohen A.S., Frangione B., Ikeda S., et al. Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 2005, 12:1-4.
19. Baethge B.A., Jacobson D.R. Amyloidosis, overview. e-medicine http://www.emedicine.com/med/topic3377.htm.
20. Gertz M.A., Comenzo R., Falk R.H., Fermand J.P., Hazenberg B.P., Hawkins P.N., et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Tours, France, 18-22 April 2004. Am J Hematol 2005, 79:319-328.
21. Vaziri N.D. Molecular mechanism of lipid disorders in nephrotic syndrome. Kidney Int 2003, 63:1964-1976.
22. Falk R.H. Diagnosis and management of the cardiac amyloidoses. Circulation 2005, 112:2047-2060.
23. Palladini G., Campana C., Klersy C., Balduini A., Vadacca G., Perfetti V., et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003, 107:2440-2445.
24. Dispenzieri A., Gertz M.A., Kyle R.A., Lacy M.Q., Burrit M.F., Therneau T.M., et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004, 104:1881-1887.
25. Tada S., Iida M., Yao T., Kitamoto T., Yao T., Fujishima M. Intestinal pseudo-obstruction in patients with amyloidosis: clinicopathologic differences between chemical types of amyloid protein. Gut 1993, 34:1412-1417.
26. Lachmann H.J., Goodman H.J., Gilbertson J.A., Gallimore J.R., Sabin C.A., Gillmore J.D., et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007, 356:2361-2371.
27. Hawkins P.N., Lavender J.P., Pepys M.B. Evaluation of systemic amyloidosis by scintigraphy with 125I-labeled serum amyloid P component. N Engl J Med 1990, 323:508-513.
28. Myllykangas-Luosujärvi R., Aho K., Kautiainen H., Hakala M. Amyloidosis in a nationwide series of 1666 subjects with rheumatoid arthritis who died during 1989 in Finland. Rheumatology 1999, 38:499-503.
29. Falck H.M., Maury C.P.J., Teppo A.M., Wegelius O. Correlation of persistently high serum amyloid A protein and C-reactive protein concentrations with rapid progression of secondary amyloidosis. BMJ 1983, 286:1391-1393.
30. Gillmore J.D., Lovat L.B., Persey M.R., Pepys M.B., Hawkins P.N. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001, 358:24-29.
31. Kisilevsky R., Young I.D. Pathogenesis of amyloidosis. Baillieres Clin Rheumatol 1994, 8:613-626.
32. Cunnane G., Whitehead A.S. Amyloid precursors and amyloidosis in rheumatoid arthritis. Baillieres Clin Rheumatol 1999, 13:615-628.
33. Röcken C., Shakespeare A. Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch 2002, 440:111-122.
34. Booth D.R., Booth S.E., Gillmore J.D., Hawkins P.N., Pepys M.B. SAA1 alleles as risk factors in reactive systemic amyloidosis. Amyloid 1998, 5:262-265.
35. Savolainen H.A., Ylijoki H.E. Declining prevalence of secondary amyloidosis in JCA. Clin Exp Rheumatol 1995, 13:551.
36. Laiho K., Tiitinen S., Kaarela K., Helin H., Isomäki H. Secondary amyloidosis has decreased in patients with inflammatory joint disease in Finland. Clin Rheumatol 1999, 18:112-113.
37. Nakano M., Ueno M., Nishi S., Shimada H., Hasegawa H., Watanabe T., et al. Analysis of renal pathology and drug history in 158 Japanese patients with rheumatoid arthritis. Clin Nephrol 1998, 50:154-160.
38. Hazenberg B.P.C., van Rijswijk M.H. Where has secondary amyloidosis gone?. Ann Rheum Dis 2000, 59:577-579.
39. Drenth J.P.H., van der Meer J.W.M. Hereditary periodic fever. N Engl J Med 2001, 345:1748-1757.
40. Grateau G. Clinical and genetic aspects of the hereditary periodic fever syndromes. Rheumatology 2004, 43:410-415.
41. Stojanov S., Kastner D.L. Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 2005, 17:586-599.
42. van der Hilst J.C.H., Simon A., Drenth J.P.H. Hereditary periodic fever and reactive amyloidosis. Clin Exp Med 2005, 5:87-88.
43. Gertz M.A., Lacy M.Q., Dispenzieri A., Hayman S.R. Amyloidosis. Best Practice Res Clin Haematol 2005, 18:709-727.
44. Lachmann H.J., Gallimore R., Gillmore J.D., Carr-Smith H.D., Bradwell A.R., Pepys M.B., et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003, 122:78-84.
45. Abraham R.S., Katzmann J.A., Clark R.J., Bradwell A.R., Kyle R.A., Gertz M.A. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 2003, 119:274-278.
46. Sacchettini J.C., Kelly J.W. Therapeutic strategies for human amyloid diseases. Nat Rev Drug Discov 2002, 1:267-275.
47. Skinner M., Sanchorawala V., Seldin D.C., Dember L.M., Falk R.H., Berk J.L., et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004, 140:85-93.
48. Gertz M.A., Lacy M.Q., Dispenzieri A. Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis. Bone Marrow Transplant 2000, 25:465-470.
49. Gertz M.A., Lacy M.Q., Lust J.A., Greipp P.R., Witzig T.E., Kyle R.A. Phase II trial of high-dose dexamethasone for previously treated immunoglobulin light chain amyloidosis. Am J Hematol 1999, 61:115-119.
50. Seldin D.C., Choufani E.B., Dember L.M., Wiesman J.F., Berk J.L., Falk R.H., et al. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma 2003, 3:241-246.
51. Goodman H.J.B., Lachmann H.J., Gallimore R., Bradwell A.P., Hawkins P.N. Thalidomide treatment in 99 patients with AL amyloidosis: tolerability, clonal disease response and clinical outcome. Haematologica 2005, 90(Suppl 1):203.
52. Wechalekar A.D., Goodman H.J.B., Lachmann H.J., Offer M., Hawkins P.N., Gillmore J.D. Safety and efficiacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007, 109:457-464.
53. Skinner M., Anderson J., Simms R., Falk R., Wang M., Libbey C., et al. Treatment of 100 patients with primary amyloidosis: a randomised trial of melphalan, prednisone and colchicine versus colchicine alone. Am J Med 1996, 100:290-298.
54. Kyle R.A., Gertz M.A., Greipp P.R., Witzig T.E., Lust J.A., Lacy M.Q., et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone and colchicine. N Engl J Med 1997, 336:1202-1207.
55. Drewe E., McDermott E.M., Powell R.J. Treatment of the nephrotic syndrome with etanercept in patients with the tumour necrosis factor receptor-associated periodic syndrome. N Engl J Med 2000, 343:1044-1045.
56. Hawkins P.N., Lachmann H.J., Aganna E., McDermott M.F. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004, 50:607-612.
57. Uprichard J, Perry D.J. Factor X deficiency. Blood Rev 2002, 16:97-110.
58. Kiuru S., Javela K., Somer H., Kekomäki R. Altered platelet shape change in hereditary gelsolin Asp187Asn-related amyloidosis. Thromb Haemost 2000, 83:491-495.
59. Herczenik E., Bouma B., Korporaal S.J., Strangi R., Zeng Q., Gros P., et al. Activation of human platelets by misfolded proteins. Arterioscler Thromb Vasc Biol 2007, 27. 1657-6.
60. Maule S., Papotti G., Naso D., Magnino C., Testa E., Veglio F. Orthostatic hypotension: evaluation and treatment. Cardiovasc Hematol Disord Drug Targets 2007, 7:63-70.
61. Jaccard A., Moreau P., Leblond V., Leleu X., Benboubker L., Hermine O., et al. Myélome Autogreffe (MAG) and Intergroupe Francophone du Myélome (IFM) Intergroup. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007, 357:1083-1093.
62. Merlini G., Anesi E., Garini P., Perfetti V., Obici L., Ascari E., et al. Treatment of AL amyloidosis with 4'-iodo-4'deoxydoxorubicin: an update (letter). Blood 1999, 93:1112-1113.
63. Gertz M.A., Lacy M.Q., Dispenzieri A., Cheson B.D., Barlogie B., Kyle R.A., et al. A multicenter phase II trial of 4'iodo-4'deoxyrubicin (IDOX) in primary amyloidosis (AL). Amyloid 2002, 9:24-30.
64. Rajkumar S.V., Gertz M.A. Advances in the treatment of amyloidosis. N Engl J Med 2007, 356:2413-2414.
65. Raman B., Ban T., Yamaguchi K., Sakai M., Kawai T., Naiki H., et al. Metal-ion dependent effects of clioquinol on the fibril growth of an amyloid β peptide. J Biol Chem 2005, 280:16157-16162.
66. Ritchie C.W., Bush A.I., Mackinnon A., Macfarlane S., Mastwyk M., MacGregor L., et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 2003, 60:1685-1691.
67. 2 by β-amyloid-copper complexes. J Inorg Biochem 2006, 100:2117-2126.